Whether you're a sponsor overseeing multiple CMOs, a manufacturer running complex internal processes, or a CDMO serving demanding clients — your quality team is reviewing thousands of documents by hand. NexGen GxP AI reviews the complete batch documentation package, cross-checks every record, and surfaces only the exceptions that need human judgment — with mandatory HITL oversight, an immutable audit trail, and the IQ/OQ + PCCP-aligned validation evidence to defend it in an inspection. In April 2026, FDA issued its first Warning Letter citing AI misuse in GMP manufacturing (Purolea, MARCS-CMS 722591). AI you can defend to an inspector is no longer optional.
Phase 3 and commercial pharma companies outsourcing manufacturing to CMOs face a structural quality management problem — and the regulatory clock is ticking.
Phase 3 and commercial pharma companies outsourcing manufacturing to 2–5 CMOs face a structural problem: one quality team, unlimited document volume. Batch manufacturing records, Certificates of Analysis, deviation reports, and CAPA responses arrive from each CMO in different formats, on different timelines. The manual review burden is unsustainable — and the risk of missing a critical quality signal in that volume is real.
FDA issued its first Warning Letter citing AI misuse in GMP manufacturing in April 2026 (Purolea, MARCS-CMS 722591). FDA's stated standard: all AI outputs in manufacturing require Quality Unit review. FDA PCCP guidance is final. EU AI Act Annex III enforcement arrives December 2, 2027. Every company using AI in quality review without a documented HITL gate now has active enforcement exposure.
Generic AI platforms have no HITL gate and no regulatory validation — exactly the gap FDA just acted on. QMS vendors manage your internal documents, not your CMOs'. Consultants review documents manually at hourly rates, without the institutional memory to recognize patterns across batches or suppliers. No platform is designed to give a pharma sponsor real-time, audit-ready visibility across the entire CMO supply chain.
NexGen GxP AI is designed around the specific workflow of a pharma sponsor receiving quality documentation from multiple contract manufacturers. One platform. Every CMO. Every document type. Audit-ready from day one.
Our AI-extended V-model includes pre-built IQ/OQ/PQ templates, AI Performance Requirements specifications, and Ongoing Performance Monitoring protocols — built around FDA CSA, Annex 11, and PIC/S from the ground up.
Every agent action touching a GxP record generates a complete, immutable audit entry. Every decision is traceable. Every change is assessed for regulatory impact. Every human gate is enforced.
// Audit trail entry — batch release AI
agentId: "nexgen-release-v2.1.4"
decision: "RELEASE — Batch 24-1103A"
rationale: "All 14 CPPs within spec"
inputHash: "sha256:a3f8c2..."
confidence: 0.9983
humanReview: true
timestamp: "2026-03-30T14:22:07Z"
Our validation-first agentic architecture is built around the documents that matter most to a pharma sponsor — starting with what arrives from your CMOs every batch cycle.
AI-assisted review of Batch Manufacturing Records, Certificates of Analysis, deviation reports, and CAPA closures arriving from your CMOs — with mandatory HITL gate, full audit trail, and PCCP-supporting IQ/OQ documentation.
Automated out-of-specification detection with deterministic root-cause analysis assist, CAPA linkage, and real-time SPC monitoring across production lines.
Validation-first AI modules for MES workflow orchestration, LIMS data interpretation, clinical supply planning, and supplier quality management — all on the same audit-ready infrastructure.
Our platform is designed against the specific requirements of the frameworks your quality team already knows — not adapted after the fact.
| Capability | NexGen GxP AI | Generic AI Vendors | Traditional Consultants |
|---|---|---|---|
| Pre-built validation templates (IQ/OQ/PQ) | ✓ Core | ✗ | ✗ |
| Audit-ready architecture from day one | ✓ Core | ✗ | Months to build |
| Agentic AI expertise | ✓ Core | Partial | Rare |
| 21 CFR Part 11 / Annex 11 native | ✓ Mapped by design | ✗ | Partial |
| Mandatory HITL gate (21 CFR 211.22(c)) | ✓ Enforced | ✗ | ✗ |
| PCCP-supporting IQ/OQ documentation | ✓ Included | ✗ | ✗ |
| Continuous drift monitoring | ✓ Built-in SPC | Partial | ✗ |
| AI change control automation | ✓ Automated | ✗ | Manual |
| CMO-sponsor quality management model | ✓ Purpose-built | ✗ | ✗ |
We offer a focused 30-minute briefing for quality and operations leadership — a candid look at how NexGen handles your CMO document volume with full audit-readiness.
Request a Briefing